Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
QLM2011
- Development stage
- Phase 1
- Lead developer
- Qilu Pharmaceutical
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
QLM2011 is an **investigational chemical drug** developed by Qilu Pharmaceutical (Hainan) Co., Ltd., currently in **Phase 1 clinical trials** for the treatment of **advanced malignant solid neoplasms (advanced solid tumors)**. Its precise mechanism of action has not been publicly disclosed, and there is no available information indicating a novel or targeted therapeutic mechanism. The ongoing studies are evaluating its **safety, tolerability, pharmacokinetics, and preliminary antitumor activity** in patients with advanced solid tumors[1][3][4][6][7]. There are no approved indications, and no regulatory approvals as of the latest updates.
Beyond the preview
Go deeper on QLM2011.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on QLM2011.